Authors
    • Infectious Disease
    • Internal Medicine
    • HIV
    Head of the Infectious Diseases Department, Saint-Louis Hospital in Paris
    Head of the Infectious Diseases Department, Saint-Louis Hospital in Paris
    • Professor of Infectious Diseases at University of Paris Diderot
    Jean-Michel Molina is Professor of Infectious Diseases at the University of Paris Diderot - Paris 7, and Head of the Infectious Diseases Department at the Saint-Louis Hospital in Paris. The Department of Infectious Diseases at the Saint-Louis Hospital, is mainly involved in the care of immunocompromised patients, patients with HIV-infection and patients with bone marrow and renal transplants, haematologic malignancies and cancers. Professor Molina’s primary clinical research interest lies in the area of HIV infection, initially the treatment of opportunistic infections, then the treatment of HIV-infection. He has been involved in a number of studies assessing new drugs or new strategies for the treatment of HIV infection. A cohort of more than 3,500 patients with HIV-infection is followed in his department . He is also a member of the INSERM U941 team involved in HIV basic research at the Saint-Louis hospital. Professor Molina has authored many papers in a wide variety of scientific journals, including Clinical Infectious Diseases, the Journal of Infectious Diseases, the New England Journal of Medicine, the Lancet, and AIDS. He is the Chair of the Clinical Trial Group at the French National Agency for AIDS Research (ANRS), where multicentre clinical trials are reviewed and implemented in France. Working with the ANRS, Professor Molina has been the principal investigator of a number of clinical trials in HIV-infected patients. More recently, Professor Molina has broadened his field of interest to the prevention of HIV infection with antiretrovirals and is leading the ANRS IPERGAY PrEP trial in men who have sex with men in France and Canada.
    • Infectious Disease
    • Internal Medicine
    • HIV
    • Senior Scientist at French National Institute for Medical Research
    Bruno Spire is a researcher living with HIV and is a senior scientist in the French National Institute for Medical Research. He is a member of AIDES since 1988, the main HIV non governmental organization in France and the President between 2007 and 2015. Bruno Spire was trained as Medical Doctor in Paris. He obtained his PhD in Virology in 1990 when he was working in the Françoise Barré-Sinoussi team that was involved in HIV discovery. He participated in the characterisation of HIV reverse transcriptase, described the first methods of inactivation of HIV and focused his research on molecular virology by studying the HIV Vif Protein. In 1997, he turned his research to Public Health issues, in order to reconcile the objectives of scientists and activists. He has been involved in multidisciplinary studies in order to study adherence, quality of life and risky behaviours of PLWHAs and key populations. He is leading a research team in INSERM focused on HIV community-based research. He is co-investigator of several community-based research projects on key populations including the PrEP IPERGAY trial .
    • Infectious Disease
    • Internal Medicine
    • HIV
    Pfizer Chair on Translational HIV Research, Université de Montréal
    Pfizer Chair on Translational HIV Research, Université de Montréal
    • Professor, Dept of Microbiology, Immunology, and Infectious Diseases at University of Montreal
    Cécile Tremblay is an infectious diseases/medical microbiologist specialist and the Université de Montréal/Pfizer Chair on Translational HIV Research. She is full professor in the Department of Microbiology, Immunology, and Infectious Diseases at University of Montreal and a researcher at Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CHUM). She obtained her M.D. at University of Montreal in 1992. She did her residency in medical microbiology and infectious diseases at University of Montreal and was certified by the Royal College of Physician of Canada in 1997. She then pursued a post-doctoral fellowship in HIV research at Massachusetts General Hospital, Harvard Medical School. She came back to Montreal in 2001, where she developed a research program focused on studying the virological determinants of HIV disease progression as well as molecular pathways involved in drug resistance. She is the founder and director of a pan-Canadian cohort of HIV-infected subjects with slow disease progression, which is a collaborative effort by Canadian researchers to better understand HIV immunopathology. She is also coordinating a research initiative on premature aging and cardiovascular disease in HIV in Canada. From 2012 to 2015, she served as Director of the Laboratoire de Santé Publique du Québec (Quebec Public Health Laboratory). During her mandate, she developed a research program on HIV epidemiology in Québec and was responsible for the coordination of the laboratory response to biological threats and emerging infectious diseases. She has been involved in several initiative on HIV prevention both in West Africa as well as in Canada. She is the Canadian principal investigator for the Ipergay trial which demonstrated the efficacy of pre-exposure prophylaxis in a population of gay men.
    • HIV
    Emeritus Director of the McGill University AIDS Centre
    Emeritus Director of the McGill University AIDS Centre
    • Professor of Medicine and Microbiology and Immunology at McGill Univeristy
    Dr. Mark A. Wainberg is Professor of Medicine and Microbiology and Immunology at McGill University in Montreal, Canada, and emeritus Director of the McGill University AIDS Centre. Dr. Wainberg is an internationally recognized scientist in the field of HIV/AIDS. He served as President of the International AIDS Society between 1998-2000 with responsibilities that included organization of the XIIIth International Congress on AIDS in Durban, South Africa, 2000. He was also co-Chair of the XVIth International AIDS Conference that took place in Toronto in August, 2006. He is well-known for his initial identification of 3TC as an anti-viral drug, in collaboration with BioChem Pharma Inc, in 1989, as well as for multiple contributions to the field of HIV drug resistance. His laboratory continues to work in the field of drug development and drug resistance, and, as well, Dr. Wainberg now works on efforts to achieve a cure for HIV infection. Dr. Wainberg is an elected fellow of the Royal Society of Canada and is an Officer of the Order of Canada. He is also an Officer of the Ordre National du Québec, a Chevalier in the Legion d’Honneur of France, an Honorary Fellow of the Royal College of Physicians and Surgeons of Canada, the recipient of the Killam Prize in Health Sciences for 2012, and the recipient of the Cubist-ICAAC Award of the American Society for Microbiology for outstanding achievement in research on infectious diseases, for 2014. He is also the recipient of a number of honorary doctorates. Dr. Wainberg is an author of over 500 research papers and 100 reviews and commentary articles that have appeared in the scientific literature, and is the corresponding author on most of these. He is co- Editor-in-Chief of Retrovirology, co-Editor-in-Chief of Journal of the International AIDS Society, and is a member of the editorial committees of multiple other journals. More than 30 students have obtained their Ph.D. degrees under his tutelage.
    • Infectious Disease
    • Pr at APHP Hôpital Tenon
    Head of Infectious Diseases Unit at Tenon Hospital